Australian researchers lead world in successful trial of new cancer treatment

Source: Melanoma Institute of Australia, June 2021

In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.

Relatlimab is the first immunotherapy treatment to target LAG-3, a protein in immune cells which reinvigorates and enhances the tumour fighting response.

READ THE ORIGINAL FULL ARTICLE